Avelumab plus axitinib combintion approved for untreated advanced kidney cancer in Scotland
The Sottish Medicine Consortium (SMC) have issued a final decision to recommend [...]
Biological markers of response for kidney cancer
To date, a reliable biomarker is yet to be discovered [...]
Pembrolizumab plus axitinib combination accepted by NHS Scotland for first-line treatment of advanced kidney cancer
The Sottish Medicine Consortium (SMC) have issued a final decision to [...]
Pembrolizumab plus axitinib combination declined for first-line treatment of advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) have issued [...]
Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer
KCSN are formal consultants to NICE and part of the [...]
ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer
Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib [...]
Axitinib effective as a third-line treatment for kidney cancer
A recent study published in the journal In Vivo assessed [...]
Promising efficacy and safety of seleno-L-methionine plus axitinib in advanced kidney cancer
Data from a recent phase I study of seleno-L-methionine in [...]
Axitinib first-line treatment of papillary renal cell carcinoma
The majority of renal cell carcinomas (RCCs) are a subtype [...]
Individualised axitinib dosing for patients with metastatic kidney cancer
In the following video interview with Practice Update, Dr Nancy [...]
